文献速递肿瘤 PET/CT

弥漫性大B细胞淋巴瘤的中期PET评估

Interim PET in Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Nucl Med · 2020-11-27

该研究基于449例临床试验患者的图像,比较了视觉Deauville评分与基于SUV的qPET和ΔSUVmax三种中期PET评估方法。结果显示,连续量表(qPET和ΔSUVmax)在预测无进展生存方面优于序数Deauville量表,且qPET与ΔSUVmax高度相关,所识别的低风险患者比例不足15%。

要点

  • 连续量表比序数Deauville量表更适合中期PET的预后预测。
  • qPET与ΔSUVmax在预测无进展生存方面携带基本相同的信息。
  • 所识别的低风险患者比例不足15%。

核心结论

  • 连续量表比序数Deauville量表更适合基于中期PET的预后预测。
  • qPET与ΔSUVmax基本上携带相同的信息。
  • 所识别的低风险患者比例不足15%。

研究设计与样本

  • 研究纳入449例参与「PET引导的侵袭性非霍奇金淋巴瘤治疗」试验的患者。
  • 对化疗2周期后的中期PET扫描图像进行再分析,应用视觉Deauville评分以及基于SUV的qPET和ΔSUVmax量表。
  • 计算无进展生存的阳性和阴性预测值。

主要发现

  • 使用既定阈值区分良好和不良缓解者时,Deauville的阳性预测值显著低于ΔSUVmax(38.4% vs. 56.6%;P = 0.03)。
  • qPET与ΔSUVmax在对数尺度上强相关(Pearson r = 0.75)。
  • 按对应百分位数绘制时,qPET和ΔSUVmax的阳性预测值曲线可叠加,在85百分位之前值较低,之后陡升。
  • 阴性预测值曲线也可叠加,但在80%至70%之间保持平坦。

关键数值与推荐

  • 视觉Deauville评分1-3 vs. 4-5用于区分良好和不良缓解者。
  • ΔSUVmax > 66% vs. ≤ 66%用于区分良好和不良缓解者。
  • 推荐用于识别不良缓解者的66% SUVmax下降阈值等效于qPET = 2.26,对应视觉Deauville量表评分5。

临床怎么用

  • 在中期PET评估中,可考虑使用连续量表(如qPET或ΔSUVmax)替代序数Deauville量表进行预后预测。
  • qPET与ΔSUVmax可互相替代,因其携带基本相同的信息。
  • 使用66% SUVmax下降阈值时,可对应qPET = 2.26或Deauville评分5来识别不良缓解者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In diffuse large B-cell lymphoma, early assessment of treatment response by 18F-FDG PET may trigger treatment modification. Reliable identification of good and poor responders is important. We compared 3 competing methods of interim PET evaluation. Methods: Images from 449 patients participating in the "PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" trial were reanalyzed by applying the visual Deauville score and the SUV-based qPET (q = quantitative) and ΔSUVmax scales to interim PET scans performed after 2 cycles of chemotherapy. qPET relates residual lymphoma 18F-FDG uptake to physiologic liver uptake, converting the ordinal Deauville scale into a continuous scale and permitting a direct comparison with the continuous ΔSUVmax scale, which is based on SUVmax changes between baseline and interim scans. Positive and negative predictive values were calculated for progression-free survival. Results: When established thresholds were used to distinguish between good and poor responders (visual Deauville score 1-3 vs. 4-5; ΔSUVmax > 66% vs. ≤ 66%), the positive predictive value was significantly lower with Deauville than ΔSUVmax (38.4% vs. 56.6%; P = 0.03). qPET and ΔSUVmax were strongly correlated on the log scale (Pearson r = 0.75). When plotted along corresponding percentiles, the positive predictive value curves for qPET and ΔSUVmax were superimposable, with low values up to the 85th percentile and a steep rise thereafter. The recommended threshold of 66% SUVmax reduction for the identification of poor responders was equivalent to qPET = 2.26, corresponding to score 5 on the visual Deauville scale. The negative predictive value curves were also superimposable but remained flat between 80% and 70%. Conclusion: Continuous scales are better suited for interim PET-based outcome prediction than the ordinal Deauville scale. qPET and ΔSUVmax essentially carry the same information. The proportion of poor-risk patients identified is less than 15%.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kurch L, Hüttmann A, Georgi TW, et al. Interim PET in Diffuse Large B-Cell Lymphoma. J Nucl Med. 2020. PMID: 33246974. doi:10.2967/jnumed.120.255034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。